Format

Send to

Choose Destination
Diabetes Obes Metab. 2012 Jul;14(7):596-600. doi: 10.1111/j.1463-1326.2012.01567.x. Epub 2012 Feb 20.

Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.

Author information

1
Clinical Innovations, Medco Health Solutions, Franklin Lakes, New Jersey, USA. merri_pendergrass@medco.com

Abstract

AIM:

This study evaluated whether the risk of acute renal failure (ARF) increases with exenatide and sitagliptin use.

METHODS:

A retrospective cohort study of a large medical and pharmacy claims database was performed. Data for 4 91 539 patients were analysed. Cox proportional hazard models were used to compare the risk of ARF between diabetic and non-diabetic subjects and between diabetic patients treated with exenatide, sitagliptin and control medications.

RESULTS:

Adjusted Cox analyses showed diabetic subjects had a higher risk of ARF [HR 1.51, confidence interval (CI) 1.26-1.81, p < 0.001] than non-diabetic controls. Compared with diabetic controls, neither exenatide (HR 0.77, CI 0.42-1.41, p = 0.40) nor sitagliptin (HR 1.17, CI 0.82-1.65, p = 0.39) increased the risk of ARF.

CONCLUSION:

Our study revealed an increased incidence of ARF in diabetic versus non-diabetic patients but no association between use of exenatide or sitagliptin and ARF. Because of the limitations of this observational analysis, we cannot exclude the possibility of a very small increased risk.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center